Fundraising Fox
Camp4
Founded 2016 · 62 employees on LinkedIn · 4 known investors
Find your way into Camp4
Sign up to see every warm intro you have to Camp4
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Camp4 team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Camp4 is a biotechnology company focused on genetic research and neurology, leveraging expertise in genomics and neuroscience for therapeutic development.
Also known as CAMP4 Therapeutics
Founders & leadership
Board
Investors · 4
How we know: 5AM Ventures's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: a16z's portfolio · Not right? Tell us
How we know: the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: a partner's Signal profile · Not right? Tell us
Funding
SEC filings, press & company announcements- Undisclosed amountSeries BJul 2022Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
Company profile
researched Aug 2026CAMP4 Therapeutics is a biotechnology company developing a class of RNA medicines intended to increase expression of targeted genes. Its approach uses antisense oligonucleotide (ASO) therapeutics designed to selectively upregulate gene expression by modulating regulatory RNA, with the stated aim of addressing the underlying cause of protein deficiency. The company frames inadequate gene expression as the root cause of more than a thousand diseases.
The company is advancing a pipeline of first-in-class ASO-based therapeutics aimed at diseases characterized by insufficient protein expression, and targets disease areas where patient communities have limited or no treatment options. Its leadership team is described as having expertise in RNA biology and drug development.
▸Full profile — market position, technology, go-to-market
Market position
Positions itself as pioneering a new class of RNA medicines focused on increasing, rather than reducing, targeted gene expression.
Differentiates on selective upregulation of gene expression through modulation of regulatory RNA with ASOs, addressing protein deficiency directly with stated precision and control.
Technology
The core technology is antisense oligonucleotide (ASO) therapeutics that modulate regulatory RNA in order to selectively upregulate expression of a target gene, increasing production of a deficient protein rather than silencing or replacing a gene.
Go-to-market
Patient populations with diseases caused by insufficient gene or protein expression, including disease areas with limited to no available treatment options.
Compiled by commissioned research from 1 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Related companies · 8
Companies working in the same space as Camp4.
In the news
▸Research sources · 1
primary sources listed
- Camp4camp4tx.com · web
1 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Camp4 do?
- CAMP4 Therapeutics develops antisense oligonucleotide RNA medicines designed to increase targeted gene expression.
- Who are Camp4's investors?
- Camp4's investors include 5AM Ventures, Andreessen Horowitz, Flucas Ventures, Northpond Ventures.